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Abstract
Purpose—Antitumor activity of cancer immunotherapies may elicit immune responses to 
nontargeted (secondary) tumor antigens, or antigen spread. We evaluated humoral antigen spread 
after treatment with sipuleucel-T, an immunotherapy for asymptomatic or minimally symptomatic 
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metastatic castration-resistant prostate cancer (mCRPC), designed to target prostatic acid 
phosphatase (PAP; primary antigen).
Experimental Design—Serum samples from patients with mCRPC enrolled in the placebo-
controlled phase III IMPACT study (evaluable n = 142) were used to assess humoral antigen 
spread after treatment with sipuleucel-T. Immunoglobulin G (IgG) responses to self-antigens 
(including tumor antigens) were surveyed using protein microarrays and confirmed using Luminex 
xMAP. IgG responses were subsequently validated in ProACT (n = 33), an independent phase II 
study of sipuleucel-T. Association of IgG responses with overall survival (OS) was assessed using 
multivariate Cox models adjusted for baseline prostate-specific antigen (PSA) and lactate 
dehydrogenase levels.
Results—In patients from IMPACT and ProACT, levels of IgG against multiple secondary 
antigens, including PSA, KLK2/hK2, K-Ras, E-Ras, LGALS8/PCTA-1/galectin-8, and LGALS3/
galectin-3, were elevated after treatment with sipuleucel-T (P < 0.01), but not control. IgG 
responses (≥2-fold elevation post-treatment) occurred in ≥25% of patients, appeared by 2 weeks 
after sipuleucel-T treatment, and persisted for up to 6 months. IgG responses to PSA and LGALS3 
were associated with improved OS in sipuleucel-T–treated patients from IMPACT (P ≤ 0.05).
Conclusions—Sipuleucel-T induced humoral antigen spread in patients with mCRPC. IgG 
responses were associated with improved OS in IMPACT. The methods and results reported may 
identify pharmacodynamic biomarkers of clinical outcome after sipuleucel-T treatment, and help 
in clinical assessments of other cancer immunotherapies.
Introduction
Methods for the assessment of efficacy of cancer immunotherapies are critical in both 
clinical development and practice. Radiographic measures for objective responses (e.g., 
RECIST or WHO criteria) have limitations in their assessment of the effects of 
immunotherapies that are designed to stimulate immune responses against the tumor (1–8). 
Several clinical studies have now shown that immunotherapies can result in improved overall 
survival (OS), without frequent objective responses or improving disease progression as 
assessed by radiography (2, 3, 9). Therefore, appropriate modifications of existing methods 
or alternative biomarkers of clinical outcome are needed that are indicative of these agents’ 
immunologic mechanism of action (2, 3, 6–8, 10).
Evidence of immune responses to nontargeted (secondary) antigens following treatment with 
an immunotherapy, referred to as antigen (or epitope) spread, may enable the identification 
of novel biomarkers of clinical outcome (11–17). Originally described in autoimmune 
diseases, antigen spread is believed to play an important role in the progression and 
pathogenesis of immune-related disorders (18–21) and in the protection against infectious 
diseases (22, 23). In the context of antitumor immune responses, antigen spread to tumor-
associated antigens (TAA) may be indicative of tumor cell killing, antigen release, and 
subsequent priming of self-reactive T and/or B lymphocytes against TAAs (21, 24, 25). It 
has been suggested that treatment-induced antigen spread may be associated with improved 
clinical outcomes (11–17), but evidence from controlled clinical studies is currently lacking. 
Here, we report an investigation of antigen spread and its association with OS following 
GuhaThakurta et al. Page 2
Clin Cancer Res. Author manuscript; available in PMC 2016 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
treatment with sipuleucel-T, an autologous cellular immunotherapy for the treatment of 
patients with asymptomatic or minimally symptomatic metastatic castration-resistant 
prostate cancer (mCRPC; ref. 4).
Sipuleucel-T, designed to target the prostate antigen, prostatic acid phosphatase (PAP, the 
primary antigen), prolongs OS in patients with mCRPC, but without significant 
improvement in objective measures of disease progression (4). Immune responses to PAP 
have been shown to be associated with OS in patients who received sipuleucel-T (26), but 
antigen spread to TAAs following treatment may provide a more relevant measure of an 
effective antitumor immune response (13, 25). Here, we show that sipuleucel-T, but not 
control, elicited serum antibody [immunoglobulin G (IgG)] responses to nontargeted tumor 
antigens, including prostate-specific antigen (PSA; also known as KLK3), KLK2/hK2 
(KLK2), K-Ras, E-Ras, LGALS8/PCTA-1/galectin-8 (LGALS8), and LGALS3/galectin-3 
(LGALS3). These responses were observed at 2 weeks and up to 6 months after treatment 
with sipuleucel-T. Sipuleucel-T–induced IgG responses to PSA and LGALS3 were 
associated with improved OS in IMPACT.
These results further the understanding of the mechanism of action of sipuleucel-T and may 
help to identify biomarkers of clinical outcome for this therapy. The methods and results 
presented here may also facilitate the identification of serum bio-markers of clinical 
outcome for other cancer immunotherapies. Such easily accessible biomarkers of clinical 
outcome may meet a critical need for assessing the in vivo mechanism and efficacy of this 
class of cancer therapies (10, 11, 27). Antigen spread may also help in the identification of 
TAAs that can be targeted by immunotherapies in the future.
Materials and Methods
Treatments, clinical trials, and biologic specimens
Sipuleucel-T is prepared by culturing autologous peripheral blood mononuclear cells 
(PBMC) with PA2024, a fusion protein comprising PAP and granulocyte colony-stimulating 
factor (GM-CSF; ref. 4). Sipuleucel-T was administered as a total of three infusions (or 
doses) at approximately 2-week intervals (Supplementary Fig. S1). In IMPACT, three 
infusions of a control product were administered at the same time intervals as sipuleucel-T 
(4).
IMPACT (Clinicaltrials.gov identifier NCT00065442) was a multicenter, randomized, 
double-blind, phase III clinical trial of sipuleucel-T in 512 patients with asymptomatic or 
minimally symptomatic mCRPC (4), and randomized 2:1 to the sipuleucel-T and control 
arms. For the evaluation of immune responses, the original protocol was amended to allow 
collection of peripheral samples from patients who provided consent (4, 26). Median follow-
up duration for the patients from whom serum samples were available was 33.7 months. 
ProACT (NCT00715078) is a multicenter, randomized, single-blind, phase II clinical trial of 
sipuleucel-T manufactured with three different concentrations of PA2024 and administered 
to a total of 122 patients with advanced mCRPC. All sipuleucel-T–treated patients included 
in the analyses reported here (IMPACT and ProACT) received sipuleucel-T manufactured 
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using the antigen concentration approved by the FDA and EMA (European Medicines 
Agency).
Serum samples were collected from patients at time points specified under each study 
protocol (see Supplementary Methods). In both studies, a pretreatment or baseline sample 
was collected at the time of registration. In IMPACT, samples were collected at 
approximately 2, 10, and 22 weeks after treatment (6, 14, and 26 weeks after initiation of 
treatment, respectively). In ProACT, samples were collected at approximately 4, 12, and 20 
weeks after treatment (8, 16, and 24 weeks after initiation of treatment). Other than 
pretreatment, all time points were post-treatment (e.g., “week 10” refers to week 10 after 
completion of treatment).
Pre- and posttreatment serum samples were available from a total of 224 patients from 
IMPACT (4, 26) who provided consent; 155 in the sipuleucel-T arm and 69 in the control 
arm. Serum samples were collected from patients only up to the time of objective disease 
progression (4); consequently, samples were available from more patients at earlier time 
points than at later time points. In IMPACT, pairs of serum samples were evaluable as 
follows: (i) pretreatment and week 2, n = 204 (142 sipuleucel-T and 62 control patients); (ii) 
pretreatment and week 10, n = 132 (93 sipuleucel-T, 39 control); and (iii) pretreatment and 
week 22, n = 76 (60 sipuleucel-T, 16 control).
In ProACT (all treated with sipuleucel-T), pairs of serum samples were evaluable as follows: 
(i) pretreatment and week 4, n = 33; (ii) pretreatment and week 12, n = 26; and (iii) 
pretreatment and week 20, n = 19.
Baseline demographic and clinical characteristics of the evaluated patients from IMPACT 
and ProACT are provided in Supplementary Tables S1 and S2 respectively.
Assessment of serum IgG responses using high-content protein microarray (ProtoArray)
ProtoArray v5.0 (Life Technologies Corporation) contains roughly 9,000 recombinant 
human proteins produced using a baculovirus expression system and printed on a glass slide 
under nondenaturing conditions (15, 28–30). ProtoArray was used to measure levels of IgG 
to these proteins in pretreatment and posttreatment serum samples from patients in IMPACT 
(Fig. 1 and Table 1). IgGs bound to the proteins on the array were detected using anti-human 
IgG conjugated to Alexa Fluor 647. Serum samples (30 μL) were assayed by Life 
Technologies Corporation at 1:500 dilution (see Supplementary Methods for experimental 
details, data acquisition, and normalization). Normalized signal intensities were log2-
transformed before analysis.
At the time of the ProtoArray analysis, serum samples from pretreatment and all three 
posttreatment time points were available from 47 patients in the sipuleucel-T arm and 13 in 
the control arm in IMPACT. ProtoArray analyses were performed on samples from all 13 
patients from the control arm, and a randomly chosen subset of 28 patients from the 
sipuleucel-T arm (to ensure successful analysis of roughly 25 samples from each time 
point). After eliminating failed assays and array quality control, Proto-Array data were 
available for analysis from the following patients: (i) pretreatment and 2 weeks, 25 
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sipuleucel-T and 12 control, (ii) pretreatment and 10 weeks, 24 sipuleucel-T and 11 control, 
(iii) pretreatment and 22 weeks, 24 sipuleucel-T and 13 control.
Assessment of serum IgG responses posttreatment using Luminex xMAP
IgGs levels against candidate antigens were evaluated by Life Technologies Corporation 
using Luminex xMAP, which uses multiplexed antigen-conjugated, spectrally 
distinguishable, fluorescent (31). All available pre- and posttreatment serum sample pairs 
from IMPACT and ProACT patients were evaluated. Samples (30 μL) were assessed at a 
1:200 dilution (see Supplementary Methods). Normalized signal intensities were log2-
transformed before analysis.
Statistical analyses
Statistical analyses were performed in the “R” computing environment (http://cran.us.r-
project.org/). Statistical tests were two-sided, unless stated otherwise. Changes in serum IgG 
levels are reported relative to pretreatment (e.g., “fold change in IgG level at week 10” refers 
to the ratio of IgG level at week 10 to that at pretreatment).
Comparing pre- and posttreatment serum IgG levels from Proto-Array—To 
assess the statistical significance of pre- to posttreatment changes in levels of IgGs, 
normalized signal intensities (log2) from ProtoArray assays were tested using a moderated 
paired t test (limma, R/Bioconductor; ref. 32). The Benjamini and Hochberg procedure was 
used to perform multiple testing adjustment of P values and obtain estimated false discovery 
rates (FDR; percentage false discoveries estimated at a certain P value; ref. 33).
Comparing pre- and posttreatment serum IgG levels from Luminex xMAP—To 
evaluate increases in IgG levels after treatment, pre- and posttreatment signal intensities 
(log2) from Luminex xMAP were compared using a one-sided paired Wilcoxon signed-rank 
test. To evaluate whether the fold changes in IgG levels after treatment were higher in the 
sipuleucel-T group than in the control group, the values from the two groups were compared 
using a one-sided Wilcoxon rank-sum test. “IgG response” to an antigen was defined as ≥2-
fold increase in signal intensity posttreatment compared with pretreatment (ad-hoc 
threshold).
Evaluating association of posttreatment changes in serum IgG levels (or IgG 
responses) with OS in IMPACT—The association between posttreatment changes in 
IgG levels (or IgG responses) and OS was evaluated in the sipuleucel-T–treated patients 
from IMPACT using a two-sided Wald test on the basis of Cox models. Associations were 
evaluated with: (i) fold change (log2) in serum IgG level posttreatment, and (ii) IgG response 
status (yes/no), using univariate as well as multivariate models adjusted for baseline PSA 
and lactate dehydrogenase (LDH) levels. Baseline PSA (log10) and LDH (log10) were 
selected for use in multivariate models following the modeling approach used in other 
analyses from the IMPACT study (4, 26). Unless stated otherwise, P values from 
multivariate models are given in the text, with additional information available in 
Supplementary Results. No adjustments to P values were made for multiplicity of variables 
or posttreatment time points.
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Results
Identification of treatment-induced increases in serum IgGs to secondary antigens using 
protein microarray
We used an unbiased human protein microarray platform (ProtoArray v5.0, ≈9,000 proteins; 
refs. 15, 28–30, 34), representing a diversity of signaling pathways, oncogenes, and tumor 
antigens, to identify treatment-induced IgGs against self-antigens in IMPACT (Fig. 1; ref. 4). 
Because it was not established when the increases in levels of IgGs to secondary antigens 
may appear after treatment, we compared the pretreatment profiles to those from all 
available posttreatment time points in IMPACT, that is, weeks 2, 10, and 22 after completion 
of treatment (Supplementary Fig. S1; ref. 4). ProtoArray data from serum samples from 25 
sipuleucel-T arm and 13 control arm patients were available for analysis (see Methods).
In the sipuleucel-T arm, the numbers of unique antigens on the ProtoArray with 
corresponding increases in IgG levels (with ≥2-fold average increase across the sample set, 
and estimated FDR ≤ 10%) were: 56 at week 2, 162 at week 10, and 23 at week 22 (Fig. 1). 
In the control arm, using the same thresholds, no increases in levels of IgGs against any of 
the antigens were observed on the ProtoArray at any of these time points. In the sipuleucel-
T–treated patients, IgG against PAP (primary antigen) was highly induced at all the 
posttreatment time points (Table 1 and Supplementary Table S3). Because the number of 
antigens against which IgGs were elevated was highest at week 10, we focus the discussions 
below on further evaluation of the IgGs from this time point; IgGs from weeks 2 and 22 
were also evaluated but are discussed only briefly (with supporting information in 
Supplementary Results).
We next examined whether the sipuleucel-T–induced IgGs were targeted against antigens 
that are overexpressed in prostate tumors. Target antigens of the 100 IgGs most highly 
induced at week 10 are encoded by genes that overlapped significantly (P = 0.01) with genes 
found to be overexpressed in prostate tumors, as identified by the largest study of gene 
expression in prostate tumor and normal tissues (see Supplementary Results for details of 
the analysis; ref. 35). This suggested that after treatment with sipuleucel-T, IgGs were 
induced against antigens that are overexpressed in prostate tumors.
Confirmation of serum IgG responses to secondary antigens with Luminex xMAP
Discoveries from high-content platforms (such as microarrays) can often contain false 
positives. Therefore, IgG responses to a subset of the secondary antigens identified using 
ProtoArray were confirmed using an independent analytic platform, Luminex xMAP (31). 
We chose Luminex xMAP because of its low sample volume requirements, high reported 
sensitivity, wide linear range, and capability for multiplex IgG detection. From the 162 
secondary antigens to which IgG responses were observed with ProtoArray at week 10, we 
selected 10 for confirmation (Table 1). Of these 10 antigens, five corresponded to the IgGs 
that exhibited the highest-fold increases in level post-treatment (LGALS3, ANPEP, ECE1, 
FBXO6, and CACNG1); LGALS3 (36–38), ANPEP (39–41), ECE1 (42–45) are known to 
be expressed at high levels in prostate tumors or to have functional roles in prostate cancer 
development. We selected the remaining five antigens based on reported functional 
GuhaThakurta et al. Page 6
Clin Cancer Res. Author manuscript; available in PMC 2016 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
relevance in cancer and/or increased expression in prostate tumors, viz., KLK2 (46–48), E-
Ras (49), K-Ras (35), TSPAN13 (50), and LGALS8 (36, 51). Descriptions of the 10 
candidate antigens are provided in Supplementary Results. ProtoArray data showed that 
levels of IgGs to most of these 10 candidate secondary antigens were also elevated at the 
earlier (week 2) and later (week 22) time points (Supplementary Table S3).
Some well-known prostate tumor antigens were not present on the ProtoArray; 
consequently, no data were available from that platform regarding IgG responses to these 
antigens. We included two such antigens in the evaluations with Luminex xMAP: PSA and 
prostate-specific membrane antigen (PSMA [FOLH1]). Three additional antigens were 
evaluated for control purposes: tetanus toxoid (against which a majority of Americans are 
immunized; ref. 52), and PA2024 and PAP, the primary antigens in sipuleucel-T.
To consider IgG response to a candidate antigen as confirmed by Luminex xMAP in 
IMPACT, we required the following criteria to be satisfied (Table 2):
• In a comparison of patients from sipuleucel-T and control arms, higher fold change 
in IgG level posttreatment with sipuleucel-T (n =93) than with control (n =39), with 
P ≤0.01 for the comparison.
• In sipuleucel-T–treated patients (n =93), a significant increase in IgG levels after 
treatment compared with pretreatment (P ≤ 0.01) and ≥10% of patients, 
demonstrating an IgG response (defined as ≥2-fold increase in IgG level 
posttreatment compared with pretreatment).
Sipuleucel-T–induced increases in levels of IgGs to the following antigens were confirmed 
by Luminex xMAP: PSA, KLK2, K-Ras, E-Ras, LGALS8, and LGALS3 (Table 2 and Fig. 
2A). As expected, increases in levels of IgGs to PAP and PA2024 were also confirmed. IgG 
responses to several antigens, for example, PSA, KLK2, K-Ras, E-Ras, and LGALS3, were 
observed in ≥25% (range, 28%–44%) of the sipuleucel-T–treated patients from IMPACT. A 
5-fold increase in anti-PSA, anti-K-Ras, or anti-E-Ras IgG level was observed in ≥10% 
(range, 12%–15%) of sipuleucel-T–treated patients. Levels of IgGs to these antigens were 
not significantly elevated after treatment in the control patients (P > 0.01; Table 2).
In the evaluable patients treated with sipuleucel-T in IMPACT, changes in levels of IgGs at 
week 10 against the confirmed secondary antigens were not associated (P > 0.01) with the 
prognostic baseline characteristics reported by Halabi and colleagues (baseline serum PSA, 
LDH, albumin, or hemoglobin, total Gleason score, metastatic disease site or Eastern 
Cooperative Oncology Group [ECOG] performance status; refs. 53, 54), or prior therapeutic 
interventions (chemotherapy, radiotherapy, radical prostatectomy, or bisphosphonates; data 
not shown).
Overlap among serum IgG responders in the sipuleucel-T arm from IMPACT
To determine whether sipuleucel-T–treated patients shared IgG responses to the same 
secondary antigens, we evaluated overlaps among IgG responders (see Venn diagrams in 
Fig. 2B for representative examples, and Supplementary Table S5 for details). The majority 
of the sipuleucel-T–treated patients who had IgG responses to secondary antigens 
GuhaThakurta et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2016 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
overlapped with those who had IgG responses to PAP (Fig. 2B, left). Although there were 
differences in the patterns of IgG responses among the patients, significant overlaps were 
also observed among IgG responders to a number of different secondary antigens (e.g., E-
Ras and KLK2, or LGALS3 and K-Ras; P ≤ 0.01, hypergeometric test). For example, when 
IgG responses to PSA, E-Ras, LGALS8, and LGALS3 were considered, 25% (23 of 93) of 
sipuleucel-T–treated patients exhibited responses to three or more of the same antigens, and 
9% exhibited responses to all four of these antigens (Fig. 2B, right). In this case, depending 
on the antigen, a minority (≤30%) of the IgG responses were unique (i.e., did not overlap 
with IgG responses to other antigens).
Validation of serum IgG responses in ProACT using Luminex xMAP
To determine whether the sipuleucel-T–induced IgG responses observed in IMPACT also 
occurred in patients from an independent clinical study of sipuleucel-T, we assessed IgG 
responses to PSA, LGALS3, E-Ras, LGALS8, K-Ras, and KLK2 in a phase II study, 
ProACT. Serum samples were available from ProACT patients (n = 26) for the week 12 time 
point, which was comparable with the week 10 time point in IMPACT. In these patients, 
levels of IgGs to PSA, KLK2, K-Ras, E-Ras, and LGALS3 were significantly elevated 
versus pretreatment (P ≤ 0.01), with 2-fold increase in ≥10% (range, 15%–31%) of patients 
(Supplementary Table S6). These results provided evidence of sipuleucel-T–induced IgG 
responses to multiple secondary antigens in an independent cohort.
Association of sipuleucel-T–induced changes in serum IgG levels with OS in IMPACT
The association of sipuleucel-T–induced changes in IgG levels at week 10 with OS was 
evaluated in IMPACT using a multivariate Cox model, adjusted for baseline PSA and LDH 
levels. Sipuleucel-T–induced changes in levels of anti-PSA IgG [hazard ratio (HR), 0.63; 
95% confidence interval (CI), 0.46–0.86; P < 0.01] and anti-LGALS3 IgG (HR, 0.60; 95% 
CI, 0.38–0.96; P = 0.04) were significantly associated with improved OS (Fig. 3 and 
Supplementary Table S7A). Sipuleucel-T–induced changes in levels of anti-KLK2 IgG and 
anti-E-Ras IgG showed a trend toward association with improved OS (0.05 < P < 0.1).
In the sipuleucel-T arm, IgG responses (≥2-fold increase at week 10) to PSA (responders, n 
= 36; nonresponders, n = 57; HR, 0.38; 95% CI, 0.19–0.80; P = 0.01) and LGALS3 
(responders, n = 26; nonresponders, n = 67; HR, 0.25; 95% CI, 0.09–0.72; P = 0.01) were 
also significantly associated with improved OS (Supplementary Table S7B). Relative to 
patients in the control arm, patients in the sipuleucel-T arm who were anti-PSA IgG 
responders exhibited significantly improved OS (HR, 0.27; 95% CI, 0.12–0.58; P < 0.01; 
Fig. 4 and Supplementary Table S8), whereas OS in patients in the sipuleucel-T arm who 
were anti-PSA IgG nonresponders did not differ significantly from that in patients in the 
control arm (HR, 0.71; 95% CI, 0.41–1.23; P = 0.23). Similarly, patients in the sipuleucel-T 
arm who were anti-LGALS3 IgG responders exhibited significantly improved OS compared 
with those in the control arm (HR, 0.16; 95% CI, 0.06–0.49; P < 0.01; Fig. 4), whereas OS 
in patients in the sipuleucel-T arm who were anti-LGALS3 IgG nonresponders did not differ 
significantly from patients in the control arm (HR, 0.66; 95% CI, 0.38–1.12; P = 0.12). 
These results indicate that a relatively moderate increase in levels of IgGs to secondary 
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antigens (≥2-fold) may identify patients who are more likely to have significant survival 
benefit after sipuleucel-T treatment than patients who do not show increase in these IgGs.
We next tested whether increasing numbers of IgG responses to secondary antigens was 
associated with progressively improved OS. Interestingly, as compared with patients with no 
IgG responses against the confirmed antigens (namely, PSA, LGALS3, E-Ras, LGALS8, K-
Ras, and KLK2; n = 26), patients with ≥1 (n = 67; HR, 0.57; 95% CI, 0.29–1.10; P =0.09), 
≥2 (n =52; HR, 0.51; 95% CI, 0.25–1.03; P = 0.06), ≥3 (n = 34; HR, 0.39; 95% CI, 0.17–
0.92; P = 0.03), and ≥4 (n = 26; HR, 0.30; 95% CI, 0.11–0.82; P = 0.02) IgG responses 
showed progressively improved OS (Supplementary Fig. S2). The number of patients with 
IgG responses ≥5 was small (n ≤ 17), therefore, patients with ≥5 IgG responses were not 
analyzed. Overall, these data suggest that the total number of IgG responses (in other words, 
the extent of antigen spread) may be associated with improved OS.
Among patients from the sipuleucel-T arm in IMPACT, anti-PA2024 and anti-PAP IgG 
responders exhibited improved OS relative to control patients, whereas anti-PA2024 and 
anti-PAP IgG nonresponders did not (Supplementary Table S8). However, the increases in 
OS observed in the anti-PA2024 and anti-PAP IgG responders were not as significant as 
those in the anti-PSA or anti-LGALS3 IgG responders. A previous analysis of data from 
IMPACT, using different methodologies, showed that aggregated humoral (IgG and IgM 
combined) and cellular immune responses to PAP or PA2024 were associated with improved 
OS (26).
Serum IgG responses at earlier and later posttreatment time points
To determine whether the IgG responses to secondary antigens observed at the week 10 time 
point in IMPACT also occurred at other time points, we examined serum samples from the 
other available posttreatment time points in IMPACT (weeks 2 and 22) and ProACT (weeks 
4 and 20; see Supplementary Table S9 for IMPACT and Supplementary Table S10 for 
ProACT results). In IMPACT, significant (P ≤ 0.01) increases in levels of IgGs against PSA, 
KLK2, K-Ras, E-Ras, LGALS8, and LGALS3 were observed in the sipuleucel-T group at 
week 2 (n = 142) and week 22 (n = 60). In ProACT, significant increases in levels of IgGs 
against PSA, KLK2, K-Ras, E-Ras, LGALS8, and LGALS3 were observed at week 4 (n = 
33), but not at week 20 with sipuleucel-T (n = 19). The relatively small number of patients 
evaluable at week 20 in ProACT may have contributed to the lack of statistical significance.
Sipuleucel-T–induced IgG responses were largely consistent across the posttreatment time 
points. Patients from the sipuleucel-T arm in IMPACT with IgG responses to an antigen at 
week 10 frequently exhibited an IgG response to the same antigen at the earlier (week 2) and 
later (week 22) time points (P ≤ 0.01, hypergeometric test; Supplementary Table S11).
In the sipuleucel-T–treated patients from IMPACT, IgG responses to PSA at week 2 were 
significantly associated with improved OS (responders, n = 35; nonresponders, n = 107; HR, 
0.42; 95% CI, 0.22–0.79; P < 0.01; Fig. 4; Supplementary Table S12B), and IgG responses 
to LGALS3 at week 2 showed a trend toward improved OS (responders, n = 41; 
nonresponders, n = 101; HR, 0.57; 95% CI, 0.31–1.02; P = 0.06). Patients in the sipuleucel-
T arm who were anti-PSA or anti-LGALS3 IgG responders at week 2 (but not the 
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corresponding nonresponders) exhibited significantly improved OS (P < 0.01) relative to the 
patients in the control arm (Fig. 4 and Supplementary Table S13). Patients in the sipuleucel-
T arm with IgG responses to the primary antigen (PAP or PA2024) at week 2 also exhibited 
improved OS (P < 0.05; Supplementary Table S13) compared with patients in the control 
arm, whereas OS of patients without the IgG responses were not significantly different from 
patients in the control arm. IgG responses at week 22 were not significantly associated with 
OS; however, in the sipuleucel-T arm, patients with anti-PSA IgG responses showed a trend 
toward improved OS relative to nonresponders (responders, n = 18; nonresponders, n = 42; 
HR, 0.35; 95% CI, 0.12–1.05; P = 0.06; Supplementary Table S12B).
Thus, increases in levels of serum IgGs to multiple secondary antigens were observed as 
early as 2 weeks and up to 22 weeks (6 months) after completion of treatment with 
sipuleucel-T in patients from IMPACT. In the sipuleucel-T arm from IMPACT, IgG 
responses at multiple time points after treatment, spanning several months, were associated 
with improved OS.
Discussion
The results presented here show that humoral antigen spread occurred after treatment with 
sipuleucel-T. The IgG responses were not significantly associated with baseline prognostic 
characteristics or prior therapeutic interventions. Sipuleucel-T–induced IgG responses to 
PSA and LGALS3 were associated with improved OS in IMPACT.
Although antigen spread after treatment with cancer immunotherapies and its potential for 
association with clinical outcomes has been known for some time (13, 25), typically, such 
investigations have included relatively small cohorts or measured responses to a predefined 
set of antigens (11–15, 55, 56). To our knowledge, this is the most extensive demonstration 
yet of antigen spread and its relationship with clinical benefit in the context of a cancer 
immunotherapy, and the first such evaluation in a clinical study with a comparator control 
arm. The study provides insight into the temporal dynamic of the antigen spread induced by 
an immunotherapy using a broad platform (protein microarray) and demonstrates treatment-
induced IgG responses to antigens against which immune responses had not been previously 
reported in prostate cancer (K-Ras and E-Ras). Finally, these data provide evidence in a 
relatively large population that IgG responses to secondary antigens can be associated with 
improved OS, and that such responses can be observed early and persist for several months 
after treatment.
A few other studies of cancer immunotherapies (15, 17, 30, 57) have reported unbiased or 
broad evaluations of humoral responses to self-antigens; some of these are of particular 
interest in light of the results presented here. Kwek and colleagues (15) reported a higher 
frequency (or breadth) of IgG responses against self-antigens in a small cohort of patients 
with malignant melanoma who responded clinically to ipilimumab and GM-CSF; the 
majority of these responses were patient-specific. In contrast, many patients shared 
responses to the same antigens (see Fig. 2B, right, for example) in our study. This may 
reflect differences in the modes of action of sipuleucel-T and ipilimumab/GM-CSF, or more 
generally, between antigen-directed [directed toward primary tumor antigen(s)] and 
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nondirected (not directed toward specific tumor antigen[s]) immunotherapies. Compared 
with a nondirected immunotherapy (such as ipilimumab/GM-CSF), antigen spread after an 
antigen-directed immunotherapy (such as sipuleucel-T) may be limited to the antigens 
overexpressed or altered in tumor cells that express the primary antigen(s), and 
consequently, such responses may be shared among patients more often.
Using protein microarrays, Nguyen and colleagues (30) investigated antibody responses 
after treatment with GVAX, a vaccine for prostate cancer comprised two allogeneic prostate 
carcinoma cell lines, modified to secrete GM-CSF. Of the ≈30 candidate antigens against 
which antibody responses were observed after treatment (30), two (LGALS3 and LGALS8) 
were confirmed in our study; one (LGALS8) being a known prostate tumor antigen (51). 
Further studies may help determine whether immune responses to the galectins, which are 
highly expressed in prostate tumors (36), are common after treatment of prostate cancer with 
immunotherapies.
Another study used serologic analysis of expression cDNA libraries (SEREX) to investigate 
antigen spread in prostate cancer patients who received a viral vaccine encoding PSA (57). 
Of the vaccine-treated patients, 21% (7 of 30) developed antibody responses to a common 
set of ubiquitously expressed self-antigens, compared with none in the control groups. We 
did not observe responses to those antigens in our study. Patients with autoantibody 
responses after the vaccine treatment showed a trend toward decreased biochemical-free 
survival. The authors suggested that the nature of the secondary antigens may inform clinical 
outcome (57); immune responses to ubiquitously expressed self-antigens may reflect off-
target activity and be associated with adverse effects, whereas responses to tumor antigens 
may reflect antitumor immune activity and therefore be associated with improved clinical 
outcomes (12–16). In this study, all of the confirmed IgG responses were associated with (or 
showed a trend toward) improved OS (Fig. 3).
The identification of posttreatment markers of an antitumor immune response is an 
important challenge in characterizing in vivo responses to cancer immunotherapies (7, 10). 
Measuring immune responses to the primary targets of antigen-directed immunotherapies 
(12, 26, 57) is a common practice. However, questions remain regarding the appropriate 
immunologic measures that provide the best information about clinical efficacy of 
immunotherapies (7, 11). Ideally, immunologic biomarkers should reflect the therapeutic 
mechanism of action and be quantifiable from easily accessed biospecimens (11). Humoral 
responses associated with antigen spread appear to have these properties and may hold 
potential utility as pharmacodynamic biomarkers for the assessment of clinical benefits of 
some cancer immunotherapies.
The associations of IgG responses with OS after sipuleucel-T treatment should be 
considered as hypotheses-generating observations. It will be important to establish the 
optimal methods for quantifying the IgG responses (e.g., with titrations of serum or antigen-
conjugated Luminex beads) and to validate the associations with OS in additional clinical 
studies. The current results, along with previously published findings on sipuleucel-T (4, 26, 
58), also point to opportunities to further characterize the observed IgG responses and to 
understand their origin and function. Some of these are discussed below.
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Although our data do not reveal the mechanism of origin of the IgG responses (note that 
tumor specimens were not available for analyses in IMPACT or ProACT), a few 
observations argue in favor of a possible treatment-induced antitumor effect. First, in a 
neoadjuvant setting, sipuleucel-T increases the frequency of CD4+ and CD8+ T cells within 
prostate tissue 2 to 3 weeks after treatment, particularly at the tumor margin (58). Second, 
sipuleucel-T–induced antigen spread was a delayed manifestation; a higher number of IgG 
responses were observed on ProtoArray at week 10 than at week 2. Third, IgG responses 
were mounted against antigens that are overexpressed in prostate tumors (35), including 
intracellular oncogenes (e.g., Ras members). Taken together, these observations suggest a 
mechanism by which the initial immune responses mobilized by sipuleucel-T are 
responsible for some degree of tumor cell lysis and release of secondary antigens; these 
secondary antigens may have triggered the IgG responses observed here.
The induction of IgG responses suggests that CD4+ helper T cells (Th2) have been engaged. 
Both cellular and humoral responses to the primary antigen, PAP, have been reported (4, 26), 
and characterization of cytokine profiles in sipuleucel-T product indicated engagement of 
both Th1 and Th2 mechanisms (26). It will be useful to determine whether sipuleucel-T–
treated patients exhibit cellular immune responses to the secondary antigens. Combined 
cellular and humoral responses may be more effective in identifying the patients with 
antigen spread after-treatment. It is of note here that in another study, after treatment with 
PSA-TRICOM, a PSA-targeted viral vaccine for prostate cancer (59), primarily T-cell 
responses to PSA were generated, with only rare instances of anti-PSA antibody responses. 
In contrast, we found that anti-PSA IgGs were frequently induced after treatment with 
sipuleucel-T.
To date, the development of active cancer immunotherapies has focused on induction of 
CD8+ cytotoxic T-cell responses; however, recent studies have shown the importance of 
CD4+ T cells, B cells and humoral immunity in mediating tumor control (60–62). In 
particular, infiltration of plasma B cells and immunoglobulin gene expression have been 
identified as important predictors of good prognosis and response to chemotherapy (61, 62). 
The ability of IgG antibodies to mediate tumor cell killing suggests that tumor-specific 
antibodies may play a role in the overall ability of the immune system to combat tumors. 
Although the magnitudes of sipuleucel-T–induced IgG responses to secondary antigens were 
modest compared with that observed to the primary antigen, multiple IgG responses could 
collectively mediate an additive or synergistic antitumor effect. Several of the confirmed IgG 
responses were against antigens known to be involved with PSA and Ras-related molecular 
functions: PSA, KLK2, LGALS3, and K-Ras. KLK2 generates the enzymatically active 
form of PSA from pro-PSA (48). LGALS3 is cleaved by PSA, potentially modulating its 
function (38), and is a binding partner and activator in K-Ras signaling (63, 64). Whether 
there is a functional significance to the appearance of IgG responses to multiple antigens in 
this molecular pathway is unknown. It is also unclear why a subset of the confirmed IgG 
responses was more significantly associated with OS, although all showed a trend toward 
improved OS. The association of a given IgG response with OS may be determined by 
particularities of the expression or biologic role of the given antigen, or the functionality of 
the IgGs generated. Investigation of the isotypes of these IgGs and their ability to mediate 
antibody-dependent cell-mediated cytotoxicity (ADCC) and other functions (binding or 
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neutralization), individually and in combination, may help shed light on their relevance to 
antitumor responses. In this study, we have confirmed only a relatively limited number of 
IgG responses; it will be of interest in future studies to assess a wider set of IgGs than those 
characterized here. Specifically, additional candidates from the protein microarrays as well 
as known prostate cancer-related gene variants, such as the TMPRSS2–ERG fusion product 
may help in gleaning a more complete understanding of IgG responses and their functional 
relevance.
Finally, treatment-induced immune responses to secondary antigens may provide targets for 
developing future therapies (15). Therefore, it will be of interest to ask in preclinical studies 
if immunization against the particular antigens to which IgG responses were observed here 
is protective against tumor growth.
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Translational Relevance
Clinical benefits of cancer immunotherapies are often not evident with the commonly 
used radiographic measures of objective tumor response (e.g., RECIST or WHO criteria). 
Biomarkers that are indicative of immunologic antitumor activity may be useful in 
assessing the clinical benefit of this class of therapeutics. The development of immune 
responses to secondary tumor antigens not directly targeted by a therapy, or antigen 
spread, may indicate tumor cell destruction and provide biomarkers of clinical benefit. 
We show here that serum antibody (IgG) responses to secondary tumor antigens (humoral 
antigen spread) can be detected within weeks after treatment with sipuleucel-T, an 
immunotherapy for meta-static castration-resistant prostate cancer, and such responses 
can be associated with improved overall survival. These results may enable identification 
of pharmacodynamic bio-markers of clinical outcome after treatment with sipuleucel-T. 
More generally, they may constitute a useful tool for evaluating the efficacy of treatment 
regimens that include cancer immunotherapies.
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Figure 1. 
Schematic for identification of serum IgG responses to secondary antigens in IMPACT, 
using ProtoArray. IgG levels in pre- and posttreatment (Tx) serum samples were compared 
with identify IgG responses against specific proteins (antigens) on the ProtoArray (≥2-fold 
average increase in serum IgG level posttreatment relative to pretreatment, with FDR ≤ 
10%). The number of antigens against which IgG responses were observed (y-axis) at the 
three posttreatment time points (x-axis) are shown for patients in the sipuleucel-T and 
control arms.
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Figure 2. 
Confirmation of serum IgG responses to secondary antigens in patients from IMPACT using 
Luminex xMAP, and analyses of overlaps between IgG responders. A, confirmation of IgG 
responses in IMPACT, 10 weeks after treatment, using Luminex xMAP. Log2 of serum IgG 
levels (y-axes) pre- and posttreatment in the control and sipuleucel-T arms are shown. Data 
for three secondary antigens (PSA, K-Ras, and LGALS3) are shown. Serum levels of IgG 
against PAP (primary antigen) are shown for reference. See Table 2 for details. B, overlap of 
IgG responses to different antigens in patients from the sipuleucel-T arm shown using Venn 
diagrams. The numbers of patients with overlapping IgG responses to different antigens at 
week 10 are shown. Left, overlaps include IgG responses to PAP (primary antigen). Right, 
overlaps include IgG responses to secondary antigens only. IgG responders are defined as 
patients with ≥2-fold increase in serum IgG level posttreatment versus pretreatment. 
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Information on the significance of the overlaps between IgG responders to all antigens is 
given in Supplementary Table S5; representative examples are shown here.
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Figure 3. 
Association of posttreatment changes in serum levels of IgG (log2) against specified 
secondary antigens with OS in the sipuleucel-T arm in IMPACT. The Kaplan–Meier plots 
for serum level of IgG to PSA (left) or LGALS3 (right) versus OS are shown with patients 
grouped by median fold change in serum IgG level at week 10 versus pretreatment 
(≥median, <median); the dotted horizontal line indicates estimated median OS. The total 
number of patients in the analyses is given at the top right of each plot; the numbers of 
patients in the ≥median and <median groups are also shown within each of the figures. The 
forest plot below the Kaplan–Meier plots shows HR and 95% CI for the associations of 
change in serum IgG levels (log2 scale) with OS (adjusted for baseline PSA and LDH) from 
a multivariate Cox model (Supplementary Table S7A for details); blue boxes indicate HR 
and whiskers indicate 95% CI. HRs and P values for each of the IgGs are to the left of the 
forest plot. P values are shown to 3 significant digits. **, P ≤ 0.01; *, P ≤ 0.05; ●, P ≤ 0.1.
GuhaThakurta et al. Page 22
Clin Cancer Res. Author manuscript; available in PMC 2016 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
The Kaplan–Meier plots of OS for anti-PSA and anti-LGALS3 IgG responders (R) and 
nonresponders (NR) in the sipuleucel-T arm and patients from the control arm (C) in 
IMPACT. These figures show the difference in OS between the control group and the IgG 
responder or nonresponder groups in the sipuleucel-T arm. Data for IgG responses at week 2 
(left), week 10 (middle), and week 22 (right) are shown. Top, anti-PSA IgG; bottom, anti-
LGALS3 IgG. IgG responders are defined as patients with ≥2-fold increase in serum IgG 
level posttreatment relative to pretreatment. The total number of patients in the analyses is 
given at the top right of each plot; the numbers of patients in the R, NR, and C groups are 
also shown within each of the figures. The P values and HRs (whiskers indicate 95% CI) in 
the forest plot inlays indicate the significance of the difference in OS in the R and NR 
groups relative to the C group using a multivariate Cox model (adjusted for baseline PSA 
and LDH levels) as described in the methods. Refer to Supplementary Table S8 (week 10) 
and S13 (weeks 2 and 22) for detailed information.
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